Thursday, 5 November 2026European Markets

VINCI And FORESTIERE EQUAT. Have A High Dividend Yield And Return On Equity In The Industrials Sector.

Loading stream...

(vianews) - vinci (dg.pa) is among this list of stock assets with the highest dividend rate and return on equity on the industrials sector.

financial asset price forward dividend yield return on equity
vinci (dg.pa) €118.76 4.28% 16.61%
forestiere equat. (fore.pa) €645.00 0.72% 3.09%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. vinci (dg.pa)

4.28% forward dividend yield and 16.61% return on equity

vinci sa, together with its subsidiaries, engages in concessions, energy, and construction businesses in france and internationally. the concessions segment manages motorway concessions; operates airports; and highways, railways, and stadium. its energy segment provides services to the manufacturing sector, infrastructure, facilities management, and information and communication technology; and industrial and energy-related services, which includes development of renewable energy assets, as well as engineering, procurement, and construction projects in the energy sector. the construction segment engages in designing and carrying out projects, which includes general contractor; geotechnical and structural engineering and related digital activities, as well as provision of services in nuclear engineering; proximity networks with active local companies, such as building, civil engineering, roadworks, rail works, and water works; property development, including residential and commercial properties; and management of serviced residences and property services. vinci sa was founded in 1899 and is headquartered in nanterre, france.

earnings per share

as for profitability, vinci has a trailing twelve months eps of €8.18.

pe ratio

vinci has a trailing twelve months price to earnings ratio of 14.52. meaning, the purchaser of the share is investing €14.52 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.61%.

more news about vinci.

2. forestiere equat. (fore.pa)

0.72% forward dividend yield and 3.09% return on equity

la forestière equatoriale sa does not have any significant operations. the company is based in puteaux, france. la forestière equatoriale sa operates as a subsidiary of compagnie du cambodge.

earnings per share

as for profitability, forestiere equat. has a trailing twelve months eps of €3.74.

pe ratio

forestiere equat. has a trailing twelve months price to earnings ratio of 172.46. meaning, the purchaser of the share is investing €172.46 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.09%.

revenue growth

year-on-year quarterly revenue growth grew by 4200%, now sitting on 18.24k for the twelve trailing months.

moving average

forestiere equat.'s value is below its 50-day moving average of €682.90 and below its 200-day moving average of €657.80.

more news about forestiere equat..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com